ZOMETA® Safety & Tolerability - Renal Safety
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA Safety & Tolerability � Renal Safety Handle with ZOMETA



ZOMETA® 4 mg every 3 to 4 weeks has a well-characterised renal safety profile

  • Bisphosphonates, as a class, have a well-characterised renal safety profile1
  • The use of bisphosphonates has been associated with reports of renal dysfunction1
  • The renal safety profile of ZOMETA has been assessed in multiple clinical trials1,2
    • — Serious renal adverse events are uncommon


*Grade 3 is defined as serum creatinine >3x upper limit of normal (ULN).
Grade 4 is defined as serum creatinine >6x ULN.

  • Incidence of grade 3 and 4 serum creatinine elevation was comparable to pamidronate2